# OnCo record nct05909436 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05909436/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05909436", "NCT05909436" ;
  schema:name "Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors"@en ;
  schema:alternateName "Triumph-01"@en ;
  schema:description "A phase 1/2 trial of Zimberelimab in advanced solid tumours, run by Guangzhou Gloria Biosciences Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05909436/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05909436> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-10-31" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/zimberelimab/> .